PRA acknowledges and thanks the members of the Rare Disease Advisory
Committee (RDAC) who provided their valuable contributions to the
development of these guidelines.
We Carry Kevan
Partnering with Patients to Develop Meaningful Endpoints – Practical Considerations
Selection of appropriate endpoints for rare disease clinical studies can be challenging but is critical to assessing the efficacy of new medicines.…
RARE DISEASES NEWSLETTER Volume 12, February 2019
This year we are excited to be hosting PRA’s first annual World Rare Disease Day event on February 28th, 2019. The event will be held at the PRA…